COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD

The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact...

詳細記述

書誌詳細

出版年:	Фармакоэкономика
主要な著者:	E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
フォーマット:	論文
言語:	ロシア語
出版事項:	IRBIS LLC 2017-08-01
主題:	chronic obstructive pulmonary disease copd long-acting beta-agonists laba long-acting anticholinergics laac vilantererol umeclidinum bromide olodaterol tiotropium bromide fixed combination cost minimization analysis cost-effectiveness analysis budget impact analysis
オンライン･アクセス:	https://www.pharmacoeconomics.ru/jour/article/view/196